ASX Announcements

2RT Presentation Professor Robyn H Guymer Today 15 Sept 2022

ASX Announcement General AlphaRET

15 Sept, 2022

AGM Date and Directors Nominations

ASX Announcement General iTrack Molteno3 AlphaRET

14 Sept, 2022

EYE 2RT Webinar Prof Guymer

ASX Announcement General iTrack Molteno3 AlphaRET

9 Sept, 2022

EYE FY22 Appendix 4G & Governance Statement

ASX Announcement General iTrack Molteno3 AlphaRET

26 Aug, 2022

EYE FY22 Results Presentation

ASX Announcement General iTrack Molteno3 AlphaRET

26 Aug, 2022

EYE FY22 Results Announcement

ASX Announcement General iTrack Molteno3 AlphaRET

26 Aug, 2022

EYE FY22 Appendix 4E & Annual Report

ASX Announcement General iTrack Molteno3 AlphaRET

26 Aug, 2022

Nova Eye Medical Launches iTrack Advance

ASX Announcement General iTrack Molteno3 AlphaRET

8 June, 2022

2RT Pivotal Study and Regulatory Pathway Presentation

ASX Announcement General AlphaRET

3 May, 2022

Nova Eye Medical Announces Regulatory Pathway for AlphaRET 2RT in the USA

ASX Announcement General AlphaRET

3 May, 2022

Investor Presentation Half Year Results 31 December 2021

ASX Announcement General iTrack Molteno3 AlphaRET

17 Feb, 2022

Global Revenue of A$6.5m for 6 Months Ended 31 Dec 2021

ASX Announcement General iTrack Molteno3 AlphaRET

17 Feb, 2022

Half Yearly Report and Accounts

ASX Announcement General iTrack Molteno3 AlphaRET

17 Feb, 2022

Presentation - Reducing Progression Rate of Age-Related Macular Degeneration

ASX Announcement General AlphaRET

21 Dec, 2021

5-Year Efficacy and Safety of iTrack™ to be Spotlighted at ESCRS 2021

ASX Announcement General iTrack Molteno3 AlphaRET

7 Oct, 2021

For investor enquires please contact:

Mark Flynn
Nova Eye Medical Limited
W +61 416 068 733
mflynn@nova-eye.com

This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More